Monteforce-AL Tablets

Monteforce-AL Tablets are a triple-combination formulation containing Levocetirizine Dihydrochloride, Montelukast Sodium, and Ambroxol Hydrochloride (Sustained Release). This combination is specifically designed for the management of allergic and respiratory conditions associated with cough, mucus congestion, and bronchial inflammation.

Levocetirizine is a third-generation antihistamine that provides effective relief from allergic symptoms such as sneezing, rhinorrhea, and itching. Montelukast Sodium is a leukotriene receptor antagonist that reduces airway inflammation, bronchoconstriction, and allergic response, making it useful in allergic rhinitis and asthma-related symptoms. Ambroxol HCl (SR) acts as a mucolytic and expectorant, helping to loosen thick mucus and improve its clearance from the respiratory tract.

The sustained-release formulation of Ambroxol ensures prolonged action, while the combination therapy offers comprehensive control of cough, allergy, and chest congestion, improving respiratory comfort and patient compliance.

Composition
Each film-coated bilayer tablet contains:
Montelukast Sodium IP equivalent to Montelukast — 10 mg
Levocetirizine Dihydrochloride IP — 5 mg
Ambroxol Hydrochloride IP (Sustained Release) — 75 mg
Excipients — q.s.

Indications
Allergic rhinitis
Productive cough
Bronchial allergy
Chest congestion
Upper and lower respiratory tract allergies

Key Benefits
Controls allergy and airway inflammation
Relieves cough and mucus congestion
Sustained mucolytic action
Improves breathing comfort
Once-daily convenience

Dosage and Administration
As directed by the physician.

Storage
Store below 25 °C in a dry place. Protect from light.
Keep out of reach of children.

Regulatory Information
Schedule H prescription drug. To be sold by retail on the prescription of a Registered Medical Practitioner only.